Crossmark

The pharmacological and clinical aspects behind dose loading of biological disease modifying anti-rheumatic drugs (bDMARDs) in auto-immune rheumatic diseases (AIRDs): rationale and systematic narrative review of clinical evidence

Crossref DOI link: https://doi.org/10.1186/s41927-020-00130-x

Published Online: 2020-07-28

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Geurts-Voerman, Gerlienke E.

Verhoef, Lise M.

van den Bemt, Bart J. F.

den Broeder, Alfons A.
License Information

Text and Data Mining valid from 2020-07-28

Version of Record valid from 2020-07-28
More Information

Article History

Received: 27 October 2019

Accepted: 2 April 2020

First Online: 28 July 2020

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: GG: No disclosures.LV: No disclosures.BvdB: Received grant/research support from: UCB, Pfizer, Abbvie, Bristol-Myers Squibb; Speakers bureau: Pfizer, AbbVie, UCB, Biogen, Sandoz. Delivered consultancy work for UCB, Novartis and Pfizer.AdB: Investigator for BMS (abatacept), received grants from Biogen, Sanofi and Abbvie. Advisor College ter Beoordeling Geneesmiddelen Netherlands (CBG). Advisor ReumaNederland / Dutch Arthritis foundation scientific advisory board. EULAR RA recommendations member. Several investigator initiated, publicly funded, pharmaceutical trials studying tofacitinib (PRACTICAL study), rituximab (REDO and.BRIDGE PMR study), TNF inhibitors (DRESS-PS study), MTX and leflunomide (COMPLETE-PSA study), MTX in PMR (PMR-MTX study).

Document is current

Any future updates will be listed below